Cooley advised Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, on its definitive business combination agreement with Oak Hill Bio to create a publicly listed rare disease biotechnology company to advance antisense oligonucleotide therapy rugonersen for Angelman syndrome.
Research Alliance Corporation III to Combine with Oak Hill Bio